Natus Medical Inc (BABY) 35.89 $BABY Natus Medical

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Natus Medical Inc (BABY) 35.89 $BABY

Natus Medical Expands Share Repurchase Program by $20M
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 5:54AM CDT
Natus Medical Inc. (BABY) recently announced an expansion of its share repurchase program, which authorizes it to buy back additional shares worth $20 million by Jun 1, 2017.
BABY: 35.89 (-0.66), MASI: 50.99 (-1.39), EXAC: 25.65 (-0.65), CRY: 11.69 (-0.25)

Natus Announces $20 Million Share Repurchase Program
GlobeNewswire - Fri Jun 03, 6:00AM CDT
Natus Medical Incorporated (NASDAQ:BABY) announced that its Board of Directors has approved an expansion of its existing stock repurchase program, authorizing the repurchase of up to an additional $20 million of the Company's common stock. The expiration date is set for June 1, 2017.
BABY: 35.89 (-0.66)

Natus to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Natus Medical Incorporated (NASDAQ:BABY) today announced that Jim Hawkins, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference in New York City. Mr. Hawkins is scheduled to present at 3:30 p.m. EDT on Thursday, June 9, 2016.
BABY: 35.89 (-0.66)

Lifshitz & Miller Law Firm Announces Investigation of Amaya, Inc., Chiasma, Inc., Intrexon Corporation, Natus Medical Inc., NRG Yield, Inc., Sunrun Inc., TransEnterix and Vivint Solar, Inc.
PR Newswire - Mon May 09, 7:47PM CDT
Amaya, Inc. (AYA)
BABY: 35.89 (-0.66), RUN: 5.47 (-0.42), XON: 24.33 (-0.87), AYA: 14.74 (-0.65), VSLR: 2.98 (-0.12), TRXC: 1.30 (-0.09), NYLD: 14.70 (-0.21), CHMA: 2.74 (unch)

Natus to Present at UBS Global Healthcare Conference
GlobeNewswire - Mon May 09, 6:00AM CDT
Natus Medical Incorporated (NASDAQ:BABY) today announced that Jonathan Kennedy, Sr. Vice-President and Chief Financial Officer, will present at the UBS Global Healthcare Conference in New York, NY. Mr. Kennedy is scheduled to present on Tuesday, May 24 at 10:00 a.m. Eastern Time (7:00 a.m. PT).
BABY: 35.89 (-0.66)

ATTENTION NATUS SHAREHOLDERS: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Natus Medical Incorporated; Encourages Investors to Contact the Firm for Additional Information
PR Newswire - Fri Apr 22, 8:30PM CDT
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Natus Medical Incorporated (NASDAQ: BABY) and certain of its officers. Natus designs, manufactures and markets newborn care and neurology healthcare products and services worldwide.
BABY: 35.89 (-0.66)

Hagens Berman Investigates Natus Medical Inc.'s Guidance on Prepayments From the Venezuelan Government and the Timing of Insider Sales
BusinessWire - Fri Apr 22, 7:30AM CDT
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, is investigating whether Natus Medical Incorporated. (NASDAQ: BABY) issued false and misleading statements about its expected receipt of prepayments under a contract with the Venezuelan Government and the timing of certain insiders' stock sales, potentially in violation of the securities laws.
BABY: 35.89 (-0.66)

Natus Medical Inc Says Adios to Venezuela Guidance
Brian Orelli, The Motley Fool - Motley Fool - Wed Apr 20, 3:05PM CDT
Natus Medical reported revenue of $87.3 million in the first quarter, just shy of the preliminary number of "approximately $87.5 million" that was disclosed earlier this month when the company said it wasn't going to hit its guidance. That's a...
BABY: 35.89 (-0.66)

Natus Medical beats 1Q profit forecasts
Automated Insights - Wed Apr 20, 5:11AM CDT
PLEASANTON, Calif. (AP) _ Natus Medical Inc. (BABY) on Wednesday reported first-quarter profit of $8.5 million.
BABY: 35.89 (-0.66)

Natus Medical Announces Record First Quarter 2016 Financial Results
GlobeNewswire - Wed Apr 20, 5:00AM CDT
-- Record first quarter non-GAAP earnings per share of $0.34
BABY: 35.89 (-0.66)

3 Things to Watch as Natus Medical Inc Reports Earnings
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 18, 3:15PM CDT
Image source: Natus Medical. Like the previous quarter, Natus Medical 's top-line results for the first quarter are going to be unsurprising when the company reports earnings on Wednesday since the revenue number was already disclosed . In...
BABY: 35.89 (-0.66)

NATUS NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Natus Medical Inc. to Contact the Firm
BusinessWire - Fri Apr 15, 7:18PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Natus Medical Inc. ("Natus" or the "Company" (NASDAQ:BABY).
BABY: 35.89 (-0.66)

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against Natus Medical Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Fri Apr 15, 4:02PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Natus Medical Inc. ("Natus" or the "Company" (Nasdaq: BABY). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
BABY: 35.89 (-0.66)

INVESTOR ALERT: Investigation of Natus Medical Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Fri Apr 15, 12:13PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Natus Medical Inc. ("Natus" or the "Company" (NASDAQ: BABY) concerning the Company and its officers' possible violations of federal securities laws. Law Offices of Howard G. Smith is preparing a lawsuit on behalf of injured investors.
BABY: 35.89 (-0.66)

Natus Medical: A Strong Sell on Weak Q1 & Estimate Revision
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 12:00PM CDT
On Apr 7, Zacks Investment Research downgraded Natus Medical Inc (BABY) to a Zacks Rank #5 (Strong Sell).
BABY: 35.89 (-0.66), GMED: 23.69 (-0.22), ARAY: 5.03 (-0.23), ANGO: 13.34 (-0.62)

Downgrade Alert for Natus Medical (BABY)
Comtex SmarTrend(R) - Wed Apr 06, 3:24AM CDT
Natus Medical (NASDAQ:BABY) was downgraded from Outperform to Market Perform at Raymond James today. The stock closed yesterday at $29.68 on volume of 1.8 million shares, above average daily volume of 322,000. Natus Medical Incorporated is a medical device company that develops, manufactures, and markets screening products. The Company's products identify and monitor common medical disorders that may occur between conception to a baby's first birthday. Natus is selling its ALGO products for newborn hearing screening, as well as its CO-Stat products for the evaluation of jaundice.
BABY: 35.89 (-0.66)

Company News for April 05, 2016
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 9:10AM CDT
Companies in the News are: VA,ALK,BABY,PHM,YHOO,TIME,SFTBF
TIME: 16.68 (-0.83), YHOO: 36.30 (-1.48), BABY: 35.89 (-0.66), VA: 56.10 (-0.16), PHM: 18.50 (-0.66), ALK: 57.03 (-2.11)

Virgin America and Edwards rise; Brocade, PulteGroup fall
AP - Mon Apr 04, 3:37PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq stock market:
BABY: 35.89 (-0.66), TSLA: 191.41 (-4.99), VA: 56.10 (-0.16), EW: 96.37 (-2.71), BRCD: 8.97 (-0.58)

Natus Medical Announces Preliminary Revenue for the First Quarter 2016
GlobeNewswire - Mon Apr 04, 6:00AM CDT
Natus Medical Incorporated (NASDAQ:BABY) today announced preliminary revenue for is first quarter ended March 31, 2016.
BABY: 35.89 (-0.66)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ardelyx Securities Fraud Suit: Key Investor Moves

Updated Category News Views 5

Fraud Allegations: Ardelyx Under the Microscope Looks like Ardelyx has found itself neck-deep in trouble, facing a class action lawsuit over alleged securities fraud. This isn't just a storm in a teacup. We're talking about accusations of false and misleading statements tied to their commercial performance—statements that might have left investors holding the bag with...

Continue Reading
Raken Debuts Change Orders: A Game-Changer for Builds

Updated Category News Views 4

Construction Gets a Streamlined Boost with Raken's New Tool In construction, chaos often partners seamlessly with progress. But Raken is stepping in to shake things up a bit. This isn’t just another run-of-the-mill software update; this is Raken flexing its muscles in the construction tech arena. They’ve rolled out Change Orders, enhancing their project management...

Continue Reading
PrideStaff: 8 Years Strong on Franchise Times Top 400

Updated Category News Views 4

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Continue Reading
Ajman Tourism Department Hits Internal Audit Milestone

Updated Category News Views 4

A Nod to Standards in Ajman's Tourism Department Folks, it's not every day you see a government department get this kind of spotlight in the internal audit arena, yet here we are. The Ajman Department of Tourism, Culture and Media has snagged Full Conformance with Internal Audit Quality Standards. That’s not just some random feather in their cap but a signal flare in...

Continue Reading
Teamsters Secure Landmark Deal for SF Parking Workers

Updated Category News Views 4

Major Win for San Francisco's Parking Professionals Parking lots and garages across San Francisco might not be the first places you’d look for labor triumphs, but that’s exactly what almost 1,000 members of Teamsters Local 665 have achieved. Under a newly ratified four-year master contract, these parking pros snagged one of the richest deals the industry has seen. A...

Continue Reading
Lupin Secures FDA Nod for Key Injectable Drug

Updated Category News Views 4

Lupin's FDA Approval: A Strategic Play in Pharmaceuticals Ah, the thrill of a new approval! Lupin Limited has landed U.S. FDA approval for their Phytonadione Injectable Emulsion, marking a significant stride into the lucrative realm of vitamin K treatments. This approval isn't just a feather in Lupin's cap—it's a calculated move to corner a piece of the estimated $52.3...

Continue Reading
Steel Dynamics Gears Up for Q3 2026 Earnings Update

Updated Category News Views 7

Steel Dynamics Preps for Key Earnings Report Folks, we're staring down the barrel of another quarterly earnings report from Steel Dynamics, Inc., and you can bet this one is gonna have plenty of eyes glued. October 19th, 2026, that's when they'll peel back the curtain on how they fared in Q3. Now, buckle up, because this isn't just a numbers game—it’s a snapshot of...

Continue Reading
Hexaware Teams with Anthropic for Game-Changing AI Move

Updated Category News Views 4

A Bold AI Partnership on the Horizon Mutual back-slapping or a deal with authentic grit? Hexaware’s latest tango with Anthropic might just be the jolt enterprises need. Announced under the flickering fluorescent lights of Mumbai, London, and Iselin, Hexaware’s multi-year partnership with Anthropic thrusts Claude, their razor-sharp AI, right into the mix of...

Continue Reading
CME Group Unveils First Baseball Futures Market

Updated Category News Views 6

A New Pitch in the Financial Ballpark Alright, listen up: CME Group is stepping up to the plate with a game-changer. They’re rolling out the world’s first baseball futures, launching October 12, assuming regulators give the green light. Now, this isn’t just some novelty act; it’s based on the solid groundwork of their FutureSports Performance Indexes (CME FSPI),...

Continue Reading
Mexico's Beaches Shine in 2026 Best America Rankings

Updated Category News Views 5

Mexican Shores Turning Heads in 2026 This isn’t just another wave in tourism news; it’s a tidal shift towards Mexico’s sizzling beaches claiming some prime spots on the global travel stage. If you’ve got an eye for tourism dynamics, listen up because Mexico’s sun-soaked shores just snagged six spots among the top 20 beaches in the Americas, according to the...

Continue Reading

Top 5 Most Recently Viewed Articles

Join Sensorion's Upcoming Webconference for Retail Investors

Updated Category News Views 49

Unlocking Hearing Health: Sensorion's Webconference for Retail Investors Sensorion, a trailblazer in the clinical-stage biotech space, is making waves in hearing loss therapy. They’ve announced a dedicated webconference that’s exclusively for retail shareholders—yeah, those everyday investors looking to get the lowdown on where their money's going. The Lowdown on...

Continue Reading
Mantle Network Revolutionizes Crypto with ZK Validity Rollup

Updated Category News Views 93

Transforming the Crypto Landscape with ZK Rollups Mantle Network is making significant strides in the realm of blockchain technology by advancing its technical roadmap. Recently, the network established a pioneering alliance with Succinct, positioning it as the highest total value locked (TVL) ZK validity rollup within the Ethereum layer 2 ecosystem. This transition marks...

Continue Reading
Columbus Implements Share Buyback Program for Investor Value

Updated Category News Views 146

Overview of Columbus A/S Share Buyback Program Columbus A/S is actively engaging in a share buyback initiative to support its investors and enhance the overall value of the company. Announced earlier, the program permits the corporation to repurchase shares worth up to DKK 16 million from June to March the following year. Details of Recent Transactions Timeframe of...

Continue Reading
Prospect Capital Plans Fiscal Earnings Call Ahead

Updated Category News Views 87

Prospect Capital Announces Earnings Call for Fiscal Year Prospect Capital Corporation (NASDAQ: PSEC) has revealed plans for an upcoming earnings release and conference call regarding its fiscal year that ended on June 30, 2024. This report will be submitted to the Securities and Exchange Commission, providing a detailed overview of the company's financial performance....

Continue Reading
10x Genomics Unveils Affordable Solutions for Single Cell Analysis

Updated Category News Views 90

Innovations in Single Cell Analysis by 10x Genomics At the recent Human Cell Atlas General Meeting, 10x Genomics, Inc. (NASDAQ: TXG) unveiled groundbreaking plans that promise to revolutionize single cell analysis. This exciting announcement is a significant step towards making advanced single cell technology accessible to researchers across the globe. Affordable...

Continue Reading